Referencias bibliográficas 1. Anon. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995; 44 (RR-12): 1-13. 2. Arca P, Reguera G, Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997; 40: 393-9. 3. Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 47: 471-505. 4. Belshaw PJ, Walsh CT, Stachelhaus T. Aminoacyl-CoAs as probes of condensation domain selectivity in nonribosomal peptide synthesis. Science 1999; 284: 486-9. 5. Blumer JL, Reed MD, Knupp C. Review of the pharmacokinetics of cefepime in children. Pediatr Infect Dis J 2001; 20: 337-42. 6. Bramhill D. Bacterial cell division. Annu Rev Cell Dev Biol 1997; 13: 395-424. 7. Brötz H, Sahl HG. New insights into the mechanism of action of latabiotics-diverse biological effects by binding to the same molecular target. J Antimicrob Chemother 2000; 46: 1-6. 8. Chalker AF, Ingraham KA, Lunsford RD et al. The bacA gene, which determines bacitracin susceptibility in Streptococcus pneumoniae and Staphylococcus aureus, is also required for virulence. Microbiology 2000; 146 (Pt 7): 1547-53. 9. Chambers H. Methicillin resistance in Staphylococci: Molecular and biochemical basis and clinical implications. Clin Microb Rev 1997; 10: 781-91. 10. Cui L, Murakami H, Kuwahara-Arai K, et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276-85. 11. Dmitriev BA, Ehlers S, Rietschel ET. Layered murein revisited: A fundamentally new concept of bacterial cell wall structure, biogenesis and function. Med Microbiol Immunol 1999; 187: 173-81. 12. Faron ML, Ledeboer NA, Buchan BW. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant Enterococcus in health care setting. J Clin Microbiol 2016; 54: 2436-47. 13. Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest 2014; 124: 2836-40. 14. Ge M, Chen Z, Russel Onishi H, et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-ala D-ala. Science 1999; 284: 507-11. 15. Hakenbeck R, Coyette J. Resistant penicillin-binding proteins. Cell Mol Life Sci 1998; 54: 332- 40. 16. Johnson DH, Cunha BA. Aztreonam. Med Clin North Am 1995; 79: 733-43. 17. Koch A. Autolysis control hypotheses for tolerance to wall antibiotics. Antimicrob Agents Chemother 2001; 45: 2671-5. 18. Koch AL. Penicillin binding proteins, beta-lactams, and lactamases: Offensives, attacks, and defensive countermeasures. Crit Rev Microbiol 2000; 26: 205-20. 19. Laudano JB. Ceftaroline fosamil: A new broad-spectrum cephalosporin. J Antimicrob Chemother
2011; 66 Suppl 3: iii1-18. 20. Livermore DM, Woodford N. Carbapenemases: A problem in waiting? Curr Opin Microbiol 2000; 3: 489-95. 21. Marshall CG, Lessard AD, Park IS, et al. Glycopeptide antibiotic resistance genes in glycopeptideproducing organisms. Antimicrob Agents Chemoter 1998; 42: 2215-20. 22. Martí R, Rosell M, Pou L, et al. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol 1996; 79: 55-9. 23. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother 1998; 42: 1-17. 24. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokin 1986; 11: 257-82. 25. Naas T, Nordmann P. OXA-type beta-lactamases. Curr Pharm Des 1999; 5: 865-79. 26. Nordmann P. Trends in beta-lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998; 27 Suppl 1: S100-6. 27. Park IS, Walsh CT. D-alanyl-D-lactate and D-alanyl-D-alanine synthesis by D-alanyl-D-alanine ligase from vancomycin-resistant Leuconostoc mesenteroides. J Biol Chem 1997; 272: 9210-4. 28. Peschel A, Vuong C, Otto M, et al. The D-alanine residues of Staphylococcal aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother 2000; 44: 2845-7. 29. Podlesek Z, Comino A, Herzog-Velikonja B, et al. The role of the bacitracin ABC transporter in bacitracin resistance and collateral detergent sensitivity. FEMS Microbiol Lett 2000; 188: 103-6. 30. Pou L, Rosell M, Lopez R, Pascual C. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996; 18: 149-53. 31. Rasmussen B, Bush K. Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 1997; 41: 223-32. 32. Sauvage E, Kerff F, Terrak M, et al. The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 2008; 32:234-58. 33. Serra HA, Suarez Cordo C, Alvariñas J, et al. Transportadores celulares de drogas. El viaje de los antidiabéticos orales por el organismo. Rev Soc Arg Diabetes 2017; 51: 137-52. 34. Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs 2018; 78: 675-92. 35. Silva JC, Haldimann A, Prahalad MK et al. In vivo characterization of the type A and B vancomycin- resistant Enterococci (VRE) VanRS two components system in Escherichia coli: A nonpathogenic model for studying the VRE signal transduction pathways. Proc Natl Acad Sci USA 1998; 95: 11951- 36. Tan JS, File TM Jr. Antipseudomonal penicillins. Med Clin North Am. 1995; 79: 679-93. 37. Tzouvelekis LS, Bonomo RA. SHV-type beta-lactamases. Curr Pharm Des 1999; 5: 847-64. 38. Wendel GD Jr, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312: 1229-32. 39. West PW. Extended-spectrum beta-lactamase-producing Klebsiella spp. Br J Biomed Sci 2000; 93
Loading...
Loading...
Loading...
Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar
Editorial Sciens, Todos los Derechos Reservados 2015